Glycosaminoglycan dermatan sulfate supplementation decreases diet‐induced obesity and metabolic dysfunction in mice

Abstract

Glycosaminoglycans are complex carbohydrates used as nutraceuticals for diverse applications. We studied the potential of the glycosaminoglycan dermatan sulfate (DS) to counteract the development of diet‐induced obesity (DIO) using obesity‐prone mice fed a high‐fat diet (HFD) as a model. Oral DS supplementation protected the animals against HFD‐induced increases in whole‐body adiposity, visceral fat mass, adipocyte size, blood glucose levels, insulin resistance, and pro‐inflammatory lipids levels in brown adipose tissue (BAT) and the liver, where it largely counteracted the HFD‐induced changes in the nonpolar metabolome. Protection against DIO in the DS‐supplemented mice occurred despite higher energy intake and appeared to be associated with increased energy expenditure, higher uncoupling protein 1 expression in BAT, decreased BAT “whitening,” and an enhanced channeling of fuel substrates toward skeletal muscle. This work is the first preclinical study to examine the anti‐obesity activity of DS tested individually in vivo. The results support possible uses of DS as an active component in functional foods/supplements to manage obesity and associated metabolic diseases.